STAT+: Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments
The FDA approved a novel type of treatment for narcolepsy made by Takeda, backing a new drug class that scientists hope can be used to treat other conditions.
The Food and Drug Administration (FDA) recently approved a groundbreaking treatment for narcolepsy developed by Takeda pharmaceutical company. This new drug, Orzeyful, represents a novel treatment class that scientists hope could revolutionize the management of sleep disorders and potentially address various neurologic conditions.
The twice-daily pill, marketed as Orzeyful, is an orexin receptor agonist, designed to treat narcolepsy type 1, a debilitating condition characterized by an orexin neuron deficiency, causing daytime sleepiness and muscle weakness. Given its potential, the drug is anticipated to be highly desirable for patients who have previously experienced misuse risks and persistent sleepiness while using stimulants and sodium oxybates.
Two Phase 3 trials demonstrated that Orzeyful effectively increased daytime wakefulness, reduced daytime sleepiness, decreased muscle weakness frequency, and enhanced attentiveness among patients. For further details, refer to STAT+.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
Also reported by 1 other outlet
- FDA approves Takeda's orexin drug for narcolepsy endpoints.news
